Welcome to BioSeeker Group!

Protein Kinase Therapeutics in Oncology - Where to Commercialize?

Additional Information

Published Date Oct 29, 2009
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 1442
PDF Fact Sheet View Fact Sheet for the report Protein Kinase Therapeutics in Oncology - Where to Commercialize? in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,450.00

Quick Overview

This report is an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Protein Kinase Therapeutics in Oncology - Where to Commercialize?.

    To find out more about Protein Kinase Therapeutics in Oncology - Where to Commercialize?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Protein Kinase Therapeutics in Oncology - Where to Commercialize? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target profiles, and assesses them in 57 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights 4
3 Methodologies 6
4 Table of Contents 8
4.1 List of Figures 19
4.2 List of Tables 19
5 Introduction 30
5.1 The Scope of this Report 30
5.2 Definitions 35
5.3 Abbreviations 35
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 36
6.1 Drug Repositioning in Oncology 36
6.2 Introduction to Protein Kinase Therapeutic Targets in Oncology 37
6.2.1 Carboxy-lyase Activity Targets 39
6.2.2 Catalytic Activity Targets 40
6.2.3 Cell Adhesion Molecule Activity Targets 43
6.2.4 Chaperone Activity Targets 45
6.2.5 Cysteine-Type Peptidase Activity Targets 47
6.2.6 DNA Topoisomerase Activity Targets 49
6.2.7 G-Protein Coupled Receptor Activity Targets 51
6.2.8 Growth Factor Activity Targets 52
6.2.9 Hydrolase Activity Targets 57
6.2.10 Kinase Activity Targets 58
6.2.11 Kinase Regulator Activity Targets 68
6.2.12 Lipid Kinase Activity Targets 72
6.2.13 Lipid Phosphatase Activity Targets 79
6.2.14 Oxidoreductase Activity Targets 80
6.2.15 Peroxidase Activity Targets 81
6.2.16 Protein Binding Targets 82
6.2.17 Protein Serine/Threonine Kinase Activity Targets 84
6.2.18 Protein Threonine/Tyrosine Kinase Activity Targets 144
6.2.19 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 147
6.2.20 Protein-Tyrosine Kinase Activity Targets 148
6.2.21 Protein-Tyrosine Kinase Activity Targets 150
6.2.22 Receptor Activity Targets 174
6.2.23 Receptor Binding Targets 176
6.2.24 Receptor Signaling Complex Scaffold Activity Targets 177
6.2.25 Structural Constituent of Cytoskeleton Targets 178
6.2.26 Transcription Factor Activity Targets 179
6.2.27 Transcription Regulator Activity Targets 192
6.2.28 Translation Regulator Activity Targets 193
6.2.29 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 194
6.2.30 Transporter Activity Targets 254
6.3 The Cancer Genome Project and Protein Kinase Therapeutic Targets in Oncology 258
6.3.1 Protein Kinase Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 258
6.4 Structure-based Drug Design in Protein Kinase Therapeutics is Stimulated by Available Structure Data on Biological Targets 262
6.5 Target-Target Interactions among Identified Protein Kinase Therapeutics Targets in Oncology 265
6.6 The Drug-Target Interactome 270
6.7 Protein Expression Levels of Identified Protein Kinase Therapeutic Targets in Oncology 275
6.8 Pathway Analysis of Cancer Protein Kinase Therapeutic Targets 279
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline? 337
7.1 Terminated Drug Target Profiles of Cancer Protein Kinase Drugs 340
7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 345
7.3 Phase III Clinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 347
7.4 Phase II Clinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 350
7.5 Phase I Clinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 356
7.6 Preclinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 364
7.7 Development Profiles of All Protein Kinase Drugs in Oncology 374
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Drugs in Oncology by Compound Type 408
8.1 Small Molecules 410
8.1.1 Background 410
8.1.2 Target Profiles of Small Molecular Drugs 411
8.2 Peptide/Protein Drugs 460
8.2.1 Background 460
8.2.2 Target Profiles of Peptide and Protein Drugs 461
8.3 Antibodies and Antibody-like Structures 465
8.3.1 Background 465
8.3.2 Target Profiles of Antibody Drugs 465
8.4 Nucleic Acid Therapies 469
8.4.1 Background 469
8.4.2 Target Profiles of Nucleic Acid Drugs 470
8.5 Cell and Gene Therapy 472
8.5.1 Background 472
8.5.2 Target Profiles of Cell- and Gene Therapy Drugs 473
8.6 The Competition Through Close Mechanistic Approximation of Cancer Protein Kinase Therapeutics 475
8.7 Compound Strategies based on Sub-Cellular Localization of Protein Kinase Drug Targets in Oncology 489
9 Selecting Cancer Indications for Protein Kinase Therapeutics 496
9.1 Acute Lymphocytic Leukemia 499
9.2 Acute Myelogenous Leukemia 501
9.3 Adrenal Cancer 505
9.4 B-cell Lymphoma 506
9.5 Basal Cell Cancer 508
9.6 Benign prostatic hyperplasia 508
9.7 Biliary Cancer 509
9.8 Bladder Cancer 510
9.9 Bone Cancer 512
9.10 Brain Cancer 513
9.11 Breast Cancer 517
9.12 Carcinoid 525
9.13 Cervical Cancer 526
9.14 Chronic Lymphocytic Leukemia 528
9.15 Chronic Myelogenous Leukemia 530
9.16 Colorectal Cancer 533
9.17 Endometrial Cancer 541
9.18 Fallopian Tube Cancer 543
9.19 Gastrointestinal Cancer (general) 545
9.20 Gastrointestinal Stomach Cancer 547
9.21 Gastrointestinal Stromal Cancer 549
9.22 Head and Neck Cancer 551
9.23 Hodgkin’s Lymphoma 554
9.24 Leiomyo Sarcoma 555
9.25 Leukemia (general) 556
9.26 Lipo Sarcoma 558
9.27 Liver Cancer 559
9.28 Lung Cancer (general) 562
9.29 Lymphoma (general) 564
9.30 Mast Cell Leukemia 565
9.31 Melanoma 566
9.32 Mesothelioma 570
9.33 Myelodysplastic Syndrome 573
9.34 Myeloma 575
9.35 Nasopharyngeal Cancer 578
9.36 Neuroblastoma Cancer 579
9.37 non-Hodgkin’s Lymphoma 580
9.38 Non-Small Cell Lung Cancer 582
9.39 Oesophageal Cancer 589
9.40 Oral Cancer 592
9.41 Osteo Sarcoma 592
9.42 Ovarian Cancer 593
9.43 Pancreatic Cancer 598
9.44 Peritoneal Cancer 602
9.45 Prostate Cancer 604
9.46 Renal Cancer 609
9.47 Rhabdomyo Sarcoma 615
9.48 Sarcoma (general) 616
9.49 Small Cell Lung Cancer 619
9.50 Soft Tissue Sarcoma 621
9.51 Squamous Cell Cancer 622
9.52 Synovial Sarcoma 623
9.53 T-cell Lymphoma 624
9.54 Testicular Cancer 625
9.55 Thymoma Cancer 626
9.56 Thyroid Cancer 627
9.57 Unspecified Cancer Indication 630
10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer Therapeutic Pipeline by Investigator 650
10.1 4SC 654
10.2 AB Science 658
10.3 Abbott 662
10.4 Abiogen 670
10.5 Abraxis BioScience 674
10.6 Advenchen 679
10.7 AEgera 682
10.8 Aeterna Zentaris 686
10.9 Aida Pharmaceuticals 693
10.10 Alethia Biotherapeutics 696
10.11 Alfacell 699
10.12 AlphaVax 702
10.13 Ambit Biosciences 706
10.14 Amgen 713
10.15 Amphora 723
10.16 Apthera 732
10.17 Ariad 736
10.18 Arno Therapeutics 744
10.19 ArQule 747
10.20 Array BioPharma 752
10.21 Astellas 757
10.22 Astex Therapeutics 760
10.23 AstraZeneca 769
10.24 Avalon 784
10.25 Bayer 787
10.26 Benitec 794
10.27 Berkeley Lab 798
10.28 BioAxone 801
10.29 Biotecnol 804
10.30 Biotica Technology 808
10.31 Boehringer Ingelheim 812
10.32 Bristol-Myers Squibb 820
10.33 BTG 837
10.34 Calistoga Pharmaceuticals 840
10.35 Callisto Pharmaceuticals 843
10.36 Cambrex 846
10.37 CanBas 849
10.38 Cancer Research Technology 852
10.39 Catalyst Biosciences 857
10.40 Celgene 861
10.41 Cell Therapeutics 864
10.42 Cephalon 867
10.43 Chroma Therapeutics 874
10.44 CompleGen 878
10.45 Compugen 883
10.46 CoNCERT Pharmaceuticals 887
10.47 Curis 891
10.48 Cyclacel 895
10.49 Cylene Pharmaceuticals 900
10.50 Cytokine PharmaSciences 903
10.51 Cytopia 907
10.52 Dainippon Sumitomo Pharma 911
10.53 Deciphera Pharmaceuticals 914
10.54 DeveloGen 923
10.55 Dyax 927
10.56 Eisai 930
10.57 Elara Pharmaceuticals 937
10.58 Eli Lilly 940
10.59 Enkam Pharmaceuticals 948
10.60 EntreMed 952
10.61 Exelixis 955
10.62 Galapagos 970
10.63 Genentech 973
10.64 Generex 977
10.65 GlaxoSmithKline 981
10.66 GlycoGenesys 991
10.67 GPC Biotech 995
10.68 Hanmi 998
10.69 Hoffmann-La Roche 1003
10.70 Hutchison China MediTech 1011
10.71 Idera Pharmaceuticals 1014
10.72 ImClone Systems 1017
10.73 ImmunoFrontier 1023
10.74 Incyte Corporation 1027
10.75 Inhibiton Therapeutics 1030
10.76 Inovio 1033
10.77 Insmed 1036
10.78 InterMune 1039
10.79 ISU ABXIS 1042
10.80 Johnson & Johnson 1046
10.81 KAI Pharmaceuticals 1051
10.82 Kalypsys 1054
10.83 Keryx Biopharmaceuticals 1057
10.84 Kiadis 1061
10.85 Kirin Pharma 1066
10.86 KuDOS 1071
10.87 Kyowa Hakko Kirin 1074
10.88 Lexicon Pharmaceuticals 1081
10.89 Locus Pharmaceuticals 1084
10.90 Lorus Therapeutics 1087
10.91 MaxoCore Pharmaceuticals 1090
10.92 Medisyn Technologies 1093
10.93 Merck & Co 1096
10.94 MethylGene 1101
10.95 Mitsubishi Tanabe Pharma 1104
10.96 Molecular LogiX 1108
10.97 NeoPharm 1112
10.98 Nerviano Medical Sciences 1116
10.99 NicOx 1120
10.100 Nidus Laboratories 1123
10.101 NIH - The US National Institute of Health 1127
10.102 Nippon Shinyaku 1130
10.103 Non-industrial Source 1134
10.104 Novartis 1137
10.105 Novogen 1154
10.106 Oncalis 1158
10.107 Onconova 1162
10.108 OncoTherapy Science 1170
10.109 Oncothyreon 1174
10.110 OSI Pharmaceuticals 1180
10.111 Pathway Therapeutics 1192
10.112 Peregrine Pharmaceuticals 1195
10.113 Pfizer 1199
10.114 Pharmacyclics 1218
10.115 PharmaGap 1222
10.116 PharmaMar 1226
10.117 Pharmexa 1231
10.118 Phytomedics 1237
10.119 Piramal 1240
10.120 PIramed 1243
10.121 Plexxikon 1247
10.122 Provid 1250
10.123 QLT 1253
10.124 Quantum Pharmaceuticals 1257
10.125 Ras Therapeutics 1261
10.126 Reata Pharmaceuticals 1264
10.127 Receptor BioLogix 1268
10.128 Rexahn 1271
10.129 Rigel 1276
10.130 Sanofi-Aventis 1281
10.131 Sareum 1285
10.132 SBIO 1291
10.133 Scancell 1298
10.134 Schering-Plough 1301
10.135 Semafore Pharmaceuticals 1306
10.136 Sentinel Oncology 1313
10.137 SGX Pharmaceuticals 1316
10.138 Silence Therapeutics 1321
10.139 Sirna Therapeutics 1325
10.140 Sunesis 1328
10.141 SuperGen 1332
10.142 Supratek Pharma 1339
10.143 Switch Pharma 1342
10.144 Takeda 1346
10.145 Targa Therapeutics 1350
10.146 TargeGen 1355
10.147 Tekmira Pharmaceuticals 1358
10.148 Telik 1361
10.149 Thallion Pharmaceuticals 1366
10.150 Theryte 1369
10.151 ToolGen 1372
10.152 TopoTarget 1375
10.153 UCB 1380
10.154 VasGene Therapeutics 1384
10.155 Velacor Therapeutics 1387
10.156 Vertex Pharmaceuticals 1390
10.157 ViroMed 1394
10.158 Wyeth 1398
10.159 Xcovery 1410
10.160 Xencor 1414
11 Disclaimer 1418
12 Drug Index 1419
13 Company Index 1433

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Protein Kinase Drug Targets in Oncology 269
Figure 2: The Drug-Protein Interactome of Protein Kinase Drugs –Clusters I 272
Figure 3: The Drug-Protein Interactome of Protein Kinase Drugs – Clusters II 273
Figure 4: Head-to-Head Targeting Interactome of Protein Kinase Drugs 274
Figure 5: Distribution of Compound Types among Protein Kinase Drugs in Oncology 489
Figure 6: Primary Sub-cellular Localization of Drug Targets 490

4.2 List of Tables
Table 1: Competitive Pressure Force among Protein Kinase Drugs in Oncology 29
Table 2: Overall Breakdown of the Included Protein Kinase Pipeline by Cancer Indication and Stage of Development 29
Table 3: Overview of Drug Target Profile Themes 36
Table 4: Terminally Ceased Therapeutic Protein Kinase Targets in Oncology 37
Table 5: Drug Targets of Protein Kinase Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 258
Table 6: Identity of Protein Kinase Drug Targets with Available Biological Structures 261
Table 7: Number of Target-Target Interactions among Protein Kinase Drug Targets in Oncology 264
Table 8: Drug-Protein Interactome Clusters 269
Table 9: Protein Kinase Drug Targets with Available Protein Expression Profiles 274
Table 10: Pathway Summary 278
Table 11: Drug Targets without any Identified Assigned Pathways 278
Table 12: Pathway Profiles According to BioCarta of Protein Kinase Drug Targets in Oncology 279
Table 13: Pathway Profiles According to KEGG of Protein Kinase Drug Targets in Oncology 299
Table 14: Pathway Profiles According to NetPath of Protein Kinase Drug Targets in Oncology 331
Table 15: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness 336
Table 16: Top Competitive Protein Kinase Target Profiles in Oncology 337
Table 17: Terminated Drug Target Strategies of Protein Kinase Drugs in Oncology 339
Table 18 New and Unique Protein Kinase Target Strategies in Cancer Currently in Pre-Registration to Marketed 344
Table 19: The Competition Through Close Mechanistic Approximation Between Marketed Protein Kinase Drugs in Oncology 345
Table 20: New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase III Clinical Development 346
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Protein Kinase Drugs in Oncology 347
Table 22: New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase II Clinical Development 349
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Protein Kinase Drugs in Oncology 352
Table 24 New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase I Clinical Development 355
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Protein Kinase Drugs in Oncology 360
Table 26: New and Unique Protein Kinase Target Strategies in Oncology Currently in Preclinical Development 363
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Protein Kinase Drugs in Oncology 368
Table 28: The Progression, Maturity and Competitive Comparison of Protein Kinase Drug Target Profiles in Cancer Drug Development 373
Table 29: Overview of Compound Strategy Competition Among Protein Kinase Drugs in Oncology 408
Table 30: Overview of the Competitive Landscape of Small Molecular Protein Kinase Drugs in Oncology 410
Table 31: Head-to-Head Target Competition Between Small Molecule Protein Kinase Drugs for the Treatment of Cancer 411
Table 32: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs of Protein Kinase Therapeutics in Oncology 416
Table 33: The Progression, Maturity and Competitive Comparison of Target Profiles of Small Molecule Protein Kinase Drugs in Development 429
Table 34: Overview of the Competitive Landscape of Peptide Based Protein Kinase Drugs in Oncology 460
Table 35: The Progression, Maturity and Competitive Comparison of Target Profiles of Peptide Based Protein Kinase Drugs in Development 460
Table 36: Overview of the Competitive Landscape of Protein Based Protein Kinase Drugs in Oncology 462
Table 37: The Competition Through Close Mechanistic Approximation Between Protein Based Protein Kinase Drugs in Oncology 462
Table 38: The Progression, Maturity and Competitive Comparison of Protein Based Protein Kinase Drugs in Development 463
Table 39: Overview of the Competitive Landscape of Antibody Protein Kinase Drugs in Oncology 464
Table 40: The Competition Through Close Mechanistic Approximation Between Antibody Protein Kinase Drugs in Oncology 465
Table 41: The Progression, Maturity and Competitive Comparison of Target Profiles of Antibody Protein Kinase Drugs in Development 466
Table 42: Overview of the Competitive Landscape of Nucleic Acid Therapy Protein Kinase Drugs in Oncology 469
Table 43: The Competition Through Close Mechanistic Approximation Between Nucleic Acid Therapy Protein Kinase Drugs in Oncology 469
Table 44: The Progression, Maturity and Competitive Comparison of Target Profiles of Nucleic Acid Protein Kinase Drugs in Development 470
Table 45: Potential Forms of Cell Therapy 471
Table 46: Vectors in Gene Therapy 472
Table 47: The Progression, Maturity and Competitive Comparison of Target Profiles of Cell Therapy Based Protein Kinase Drugs in Development 472
Table 48: Overview of the Competitive Landscape of Gene Therapy Protein Kinase Drugs in Oncology 472
Table 49: The Progression, Maturity and Competitive Comparison of Target Profiles of Gene Therapy Based Protein Kinase Drugs in Development 473
Table 50: The Competition Through Close Mechanistic Approximation Among All Protein Kinase Drugs in Oncology 474
Table 51: Compound Strategies based on Sub-Cellular Localization of Protein Kinase Drug Targets in Oncology 489
Table 52: Competitive Summary of Protein Kinase Drugs by Cancer Indication 495
Table 53: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Acute Lymphocytic Leukemia 498
Table 54: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs 499
Table 55: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Acute Myelogenous Leukemia 500
Table 56: The Competition through Close Mechanistic Approximation between Acute Myelogenous Drugs 502
Table 57: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Adrenal Cancer 504
Table 58: Drug Target Profiles of Protein Kinase Drugs for the Treatment of B-cell Lymphoma 505
Table 59: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 506
Table 60: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Basal Cell Cancer 507
Table 61: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Benign Prostatic Hyperplasia 507
Table 62: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Biliary Cancer 508
Table 63: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Bladder Cancer 509
Table 64: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 510
Table 65: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Bone Cancer 511
Table 66: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Brain Cancer 512
Table 67: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 514
Table 68: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Breast Cancer 516
Table 69: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 521
Table 70: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Carcinoid 524
Table 71: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Cervical Cancer 525
Table 72: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 526
Table 73: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Chronic Lymphocytic Leukemia 527
Table 74: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 528
Table 75: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Chronic Myelogenous Leukemia 529
Table 76: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs 531
Table 77: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Colorectal Cancer 532
Table 78: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 538
Table 79: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Endometrial Cancer 540
Table 80: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Fallopian Tube Cancer 542
Table 81: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs 543
Table 82: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Cancer (general) 544
Table 83: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 545
Table 84: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stomach Cancer 546
Table 85: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 547
Table 86: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stromal Cancer 548
Table 87: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs 549
Table 88: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Head and Neck Cancer 550
Table 89: The Competition through Close Mechanistic Approximation between Head and Neck and Cancer Drugs 552
Table 90: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Hodgkin’s Lymphoma 553
Table 91: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Leiomyo Sarcoma 554
Table 92: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Leukemia (general) 555
Table 93: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lipo Sarcoma 557
Table 94: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Liver Cancer 558
Table 95: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 560
Table 96: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lung Cancer (general) 561
Table 97: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 562
Table 98: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lymphoma (general) 563
Table 99: The Competition through Close Mechanistic Approximation between Lymphoma (general) Drugs 564
Table 100: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Mast Cell Leukemia 564
Table 101: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Melanoma 565
Table 102: The Competition through Close Mechanistic Approximation between Melanoma Cancer Drugs 567
Table 103: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Mesothelioma 569
Table 104: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs 571
Table 105: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Myelodysplastic Syndrome 572
Table 106: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs 573
Table 107: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Myeloma 574
Table 108: The Competition through Close Mechanistic Approximation between Myeloma Drugs 576
Table 109: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Nasopharyngeal Cancer 577
Table 110: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Neuroblastoma Cancer 578
Table 111: Drug Target Profiles of Protein Kinase Drugs for the Treatment of non-Hodgkin’s Lymphoma 579
Table 112: The Competition through Close Mechanistic Approximation between non-Hodgkin’s Lymphoma Drugs 580
Table 113: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Non-Small Cell Lung Cancer 581
Table 114: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drug 585
Table 115: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Oesophageal Cancer 588
Table 116: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 590
Table 117: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Oral Cancer 591
Table 118: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Osteo Sarcoma 591
Table 119: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Ovarian Cancer 592
Table 120: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 595
Table 121: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Pancreatic Cancer 597
Table 122: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 600
Table 123: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Peritoneal Cancer 601
Table 124: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 602
Table 125: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Prostate Cancer 603
Table 126: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 606
Table 127: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Renal Cancer 608
Table 128: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 611
Table 129: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Rhabdomyo Sarcoma 614
Table 130: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Sarcoma (general) 615
Table 131: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs 617
Table 132: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Small Cell Lung Cancer 618
Table 133: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 619
Table 134: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Soft Tissue Sarcoma 620
Table 135: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Squamous Cell Cancer 621
Table 136: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Synovial Sarcoma 622
Table 137: Drug Target Profiles of Protein Kinase Drugs for the Treatment of T-cell Lymphoma 623
Table 138: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Testicular Cancer 624
Table 139: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Thymoma Cancer 625
Table 140: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Thyroid Cancer 626
Table 141: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 628
Table 142: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Unspecified Cancer Indication 629
Table 143: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 640
Table 144: 4SC’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 653
Table 145: AB Science’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 657
Table 146: Abbott’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 661
Table 147: Abiogen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 669
Table 148: Abraxis BioScience’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 673
Table 149: Advenchen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 678
Table 150: AEgera’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 681
Table 151: Aeterna Zentaris’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 685
Table 152: Aida Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 692
Table 153: Alethia Biotherapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 695
Table 154: Alfacell’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 698
Table 155: AlphaVax’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 701
Table 156: Ambit Biosciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 705
Table 157: Amgen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 712
Table 158: Amphora’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 722
Table 159: Apthera’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 731
Table 160: Ariad’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 735
Table 161: Arno Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 743
Table 162: ArQule’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 746
Table 163: Array BioPharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 751
Table 164: Astellas’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 756
Table 165: Astex Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 759
Table 166: AstraZeneca’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 768
Table 167: Avalon’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 783
Table 168: Bayer’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 786
Table 169: Benitec’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 793
Table 170: Berkeley Lab’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 797
Table 171: BioAxone’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 800
Table 172: Biotecnol’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 803
Table 173: Biotica Technology’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 807
Table 174: Boehringer Ingelheim’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 811
Table 175: Bristol-Myers Squibb’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 819
Table 176: BTG’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 836
Table 177: Calistoga Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 839
Table 178: Callisto Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 842
Table 179: Cambrex’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 845
Table 180: CanBas’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 848
Table 181: Cancer Research Technology’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 851
Table 182: Catalyst Biosciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 856
Table 183: Celgene’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 860
Table 184: Cell Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 863
Table 185: Cephalon’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 866
Table 186: Chroma Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 873
Table 187: CompleGen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 877
Table 188: Compugen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 882
Table 189: CoNCERT Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 886
Table 190: Curis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 890
Table 191: Cyclacel’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 894
Table 192: Cylene Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 899
Table 193: Cytokine PharmaSciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 902
Table 194: Cytopia’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 906
Table 195: Dainippon Sumitomo Pharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 910
Table 196: Deciphera Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 913
Table 197: DeveloGen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 922
Table 198: Dyax’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 926
Table 199: Eisai’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 929
Table 200: Elara Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 936
Table 201: Eli Lilly’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 939
Table 202: Enkam Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 947
Table 203: EntreMed’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 951
Table 204: Exelixis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 954
Table 205: Galapagos’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 969
Table 206: Genentech’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 972
Table 207: Generex’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 976
Table 208: GlaxoSmithKline’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 980
Table 209: GlycoGenesys’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 990
Table 210: GPC Biotech’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 994
Table 211: Hanmi’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 997
Table 212: Hoffmann-La Roche’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1002
Table 213: Hutchison China MediTech’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1010
Table 214: Idera Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1013
Table 215: ImClone Systems’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1016
Table 216: ImmunoFrontier’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1022
Table 217: Incyte Corporation’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1026
Table 218: Inhibiton Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1029
Table 219: Inovio’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1032
Table 220: Insmed’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1035
Table 221: InterMune’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1038
Table 222: ISU ABXIS’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1041
Table 223: Johnson & Johnson’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1045
Table 224: KAI Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1050
Table 225: Kalypsys’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1053
Table 226: Keryx Biopharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1056
Table 227: Kiadis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1060
Table 228: Kirin Pharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1065
Table 229: KuDOS’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1070
Table 230: Lexicon Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1080
Table 231: Locus Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1083
Table 232: Lorus Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1086
Table 233: MaxoCore Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1089
Table 234: Medisyn Technologies’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1092
Table 235: Merck & Co’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1095
Table 236: MethylGene’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1100
Table 237: Mitsubishi Tanabe Pharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1103
Table 238: Molecular LogiX’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1107
Table 239: NeoPharm’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1111
Table 240: Nerviano Medical Sciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1115
Table 241: NicOx’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1119
Table 242: Nidus Laboratories’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1122
Table 243: NIH’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1126
Table 244: Nippon Shinyaku’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1129
Table 245: Non-industrial Source’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1133
Table 246: Novartis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1136
Table 247: Novogen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1153
Table 248: Oncalis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1157
Table 249: Onconova’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1161
Table 250: OncoTherapy Science’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1169
Table 251: Oncothyreon’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1173
Table 252: OSI Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1179
Table 253: Pathway Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1191
Table 254: Peregrine Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1194
Table 255: Pfizer’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1198
Table 256: Pharmacyclics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1217
Table 257: PharmaGap’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1221
Table 258: PharmaMar’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1225
Table 259: Pharmexa’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1230
Table 260: Phytomedics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1236
Table 261: Piramal’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1239
Table 262: PIramed’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1242
Table 263: Plexxikon’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1246
Table 264: Provid’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1249
Table 265: QLT’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1252
Table 266: Quantum Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1256
Table 267: Ras Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1260
Table 268: Reata Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1263
Table 269: Receptor BioLogix’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1267
Table 270: Rexahn’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1270
Table 271: Rigel’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1275
Table 272: Sanofi-Aventis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1280
Table 273: Sareum’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1284
Table 274: SBIO’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1290
Table 275: Scancell’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1297
Table 276: Schering-Plough’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1300
Table 277: Semafore Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1305
Table 278: Sentinel Oncology’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1312
Table 279: SGX Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1315
Table 280: Silence Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1320
Table 281: Sirna Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1324
Table 282: Sunesis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1327
Table 283: SuperGen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1331
Table 284: Supratek Pharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1338
Table 285: Switch Pharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1341
Table 286: Takeda’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1345
Table 287: Targa Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1349
Table 288: TargeGen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1354
Table 289: Tekmira Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1357
Table 290: Telik’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1360
Table 291: Thallion Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1365
Table 292: Theryte’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1368
Table 293: ToolGen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1371
Table 294: TopoTarget’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1374
Table 295: UCB’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1379
Table 296: VasGene Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1383
Table 297: Velacor Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1386
Table 298: Vertex Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1389
Table 299: ViroMed’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1393
Table 300: Wyeth’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1397
Table 301: Xcovery’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1409
Table 302: Xencor’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1413

This report includes 160 investigators plus their collaborators:
4SC
AB Science
Abbott
Abiogen
Abraxis BioScience
Advenchen
AEgera
Aeterna Zentaris
Aida Pharmaceuticals
Alethia Biotherapeutics
Alfacell
AlphaVax
Ambit Biosciences
Amgen
Amphora
Apthera
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Therapeutics
AstraZeneca
Avalon
Bayer
Benitec
Berkeley Lab
BioAxone
Biotecnol
Biotica Technology
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calistoga Pharmaceuticals
Callisto Pharmaceuticals
Cambrex
CanBas
Cancer Research Technology
Catalyst Biosciences
Celgene
Cell Therapeutics
Cephalon
Chroma Therapeutics
CompleGen
Compugen
CoNCERT Pharmaceuticals
Curis
Cyclacel
Cylene Pharmaceuticals
Cytokine PharmaSciences
Cytopia
Dainippon Sumitomo Pharma
Deciphera Pharmaceuticals
DeveloGen
Dyax
Eisai
Elara Pharmaceuticals
Eli Lilly
Enkam Pharmaceuticals
EntreMed
Exelixis
Galapagos
Genentech
Generex
GlaxoSmithKline
GlycoGenesys
GPC Biotech
Hanmi
Hoffmann-La Roche
Hutchison China MediTech
Idera Pharmaceuticals
ImClone Systems
ImmunoFrontier
Incyte Corporation
Inhibiton Therapeutics
Inovio
Insmed
InterMune
ISU ABXIS
Johnson & Johnson
KAI Pharmaceuticals
Kalypsys
Keryx Biopharmaceuticals
Kiadis
Kirin Pharma
KuDOS
Kyowa Hakko Kirin
Lexicon Pharmaceuticals
Locus Pharmaceuticals
Lorus Therapeutics
MaxoCore Pharmaceuticals
Medisyn Technologies
Merck & Co
MethylGene
Mitsubishi Tanabe Pharma
Molecular LogiX
NeoPharm
Nerviano Medical Sciences
NicOx
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Novartis
Novogen
Oncalis
Onconova
OncoTherapy Science
Oncothyreon
OSI Pharmaceuticals
Pathway Therapeutics
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Phytomedics
Piramal
PIramed
Plexxikon
Provid
QLT
Quantum Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Rexahn
Rigel
Sanofi-Aventis
Sareum
SBIO
Scancell
Schering-Plough
Semafore Pharmaceuticals
Sentinel Oncology
SGX Pharmaceuticals
Silence Therapeutics
Sirna Therapeutics
Sunesis
SuperGen
Supratek Pharma
Switch Pharma
Takeda
Targa Therapeutics
TargeGen
Tekmira Pharmaceuticals
Telik
Thallion Pharmaceuticals
Theryte
ToolGen
TopoTarget
UCB
VasGene Therapeutics
Velacor Therapeutics
Vertex Pharmaceuticals
ViroMed
Wyeth
Xcovery
Xencor
This report includes 409 protein kinase drugs in oncology. From Marketed to Ceased ones.
A shortlist of drugs included are:
alvocidib
ARQ-197
axitinib
BIBW-2992
brivanib alaninate
cediranib
dasatinib
deforolimus
E-75
enzastaurin hydrochloride
erlotinib
everolimus
gefitinib
idronoxil
imatinib mesilate
lapatinib ditosylate
lestaurtinib
midostaurin
motesanib diphosphate
nilotinib
pazopanib hydrochloride
ramucirumab
sorafenib tosylate
sunitinib malate
tanespimycin
temsirolimus
vandetanib
XL-184

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Protein Kinase Therapeutics in Oncology - Where to Commercialize?.
    To find out more about Protein Kinase Therapeutics in Oncology - Where to Commercialize?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Protein Kinase Therapeutics in Oncology - Where to Commercialize? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio of leukemia products. Learn More


A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market
This report comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 companies, from Ceased to Marketed. The report extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and eight subindications of leukemia. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Melanoma, Prostate Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Peptides. Learn More


Chemokine Signaling Pathway in Cancer Drug Pipeline Update
BioSeeker Group have identified 232 companies plus partners who are today developing 323 chemokine signaling pathway targeting drugs in 1189 developmental projects in cancer across 177 different targets. In addition, there are 3 suspended drugs and another 127 drugs where development has been ceased. Learn More